Q3 2024 Amarin Corporation PLC Earnings Call Transcript
Key Points
- VASCEPA/VAZKEPA has significant growth potential globally, particularly in Europe, with IP protection extended to 2039.
- The company has secured pricing and reimbursement in several European countries, including Greece and Portugal, and is making progress in Italy.
- Amarin Corp PLC (AMRN) has maintained a 50% market share in the U.S. despite generic competition, demonstrating the product's unique value.
- The company has a strong cash position with $306 million in cash and investments and no debt, providing financial stability.
- Amarin Corp PLC (AMRN) is expanding its global reach with partnerships in nine countries, including recent launches in Australia and China.
- Total net revenue decreased significantly from $66.1 million in Q3 2023 to $42.3 million in Q3 2024, primarily due to U.S. market challenges.
- U.S. product revenue declined sharply due to generic competition and changes in coverage by major insurers like CVS.
- Gross margin dropped from 64% to 38% year-over-year, reflecting pricing pressures in the U.S. market.
- The company reported a GAAP net loss of $25.1 million for Q3 2024, up from a $19.3 million loss in the prior year period.
- Amarin Corp PLC (AMRN) faces ongoing challenges in securing reimbursement and market access in Europe, which is a slow and complex process.
Welcome to Amarin Corporation's conference call to discuss its third quarter 2024 business update and financial results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
Good afternoon, everyone, and thank you for joining us. Turning to Slide 2 and our forward-looking statements. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided under federal securities law. We may not achieve our goals, carry out our plans or intentions or meet the expectations disclosed in our forward-looking statements. Actual results or events could differ materially, so you should not place undue reliance on these statements.
We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
